Skip to main content

Table 3 Differences in the cytokine levels at day −7 and day + 14 of HSCT between the grade 2–4 acute GVHD group and the other group (n = 30)

From: The soluble VCAM-1 level is a potential biomarker predicting severe acute graft versus host disease after allogeneic hematopoietic cell transplantation

 

day − 7a

  

day + 14a

 

Cytokine, mean ± SE

Acute GVHD, grade 2–4 (n = 17)

Othersb (n = 13)

P-value*

Acute GVHD, grade 2–4 (n = 17)

Othersa (n = 13)

P-value*

β2- MG, ng/ml

4311.8 ± 712.9

4582.8 ± 765.5

0.711

6306.8 ± 617.4

4794.1 ± 761.5

0.145

sVCAM-1, ng/ml

1191.2 ± 101.3

841.0 ± 104.3

0.028

1787 ± 109.3

1389.1 ± 125.3

0.035

PF4, ng/ml

394.4 ± 37.4

422.2 ± 43.1

0.563

308.0 ± 37.7

321.6 ± 34.6

0.805

TNFSF-14, ng/ml

35.9 ± 4.6

30.8 ± 3.5

0.621

24.3 ± 2.7

32.5 ± 3.6

0.086

  1. HSCT Allogeneic hematopoietic stem cell transplantation, GVHD Graft versus host disease; β2- MG Beta2-microglobulin, sVCAM-1 Soluble VCAM-1, SE Standard error of the mean
  2. aThe timepoint of the serum cytokine measurement in relation to the HSCT
  3. bIncluded patients with no acute GVHD or grade 1 acute GVHD
  4. *Mann-Whitney U test